IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of Tapphiko NAKA et al.

Serval 1002 07 687,238

Filed: Application of 18, 1991

12-C

Group Art Unit 125/201

Examiner: Not Known

For: BENZIMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND USE

LETTER ACCOMPANYING SECOND PRELIMINARY AMENDMENT

RECEIVED

BOX NON-FEE AMENDMENTS (PATS)
Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

FEB 1 1 1992

GROUP 150

3 18 EM 9: 21

Sir:

Enclosed herewith is a SECOND PRELIMINARY AMENDMENT for filing as of this date; kindly also make of record the following:

FEES FOR AMENDED CLAIMS

Excess independent claims at \$72 each -	\$
Excess total claims at \$20 each -	\$
First multiple dependent claim at \$220 extra -	\$

EXTENSION OF TIME PETITION

If this paper is filed outside the regular shortened period for response, applicant(s) petition(s) for the minimum extension of time needed to effect timely filing of the instant paper, calculated as being for a total of ____ month(s), and the fee being

\$		

[] TOTAL FEE:

Our check is included for:

\$

[X] Applicant(s) generally authorize(s) payment of any required fee for the filing of this paper (even if different from any calculation above) to our Deposit Account 23-0783 under our general authorization under 37 CFR 1.17.

WEGNER, CANTOR, MUELLER & PLAYER

P. O. BOX 18218

WASHINGTON, DC 20036-8218

(202) 887-0400

Atty. Doc.: P-4414-22823

DATE: February 6, 1992

DPM:1dc/2.53

Respectfully submitted,

Douglas P. Mueller Reg./No. 30,300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Janks 2-19-92

In re the application of FEB
Takehiko NAKA et 15. FEB
Serial No. 07/687 381992
Filed: April 18, 15 Appendix

Group Art Unit 125 Examiner: Not Known

For: BENZIMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND USE

SECOND PRELIMINARY AMENDMENT RECEIVED

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

GROUP 150

FEB 1 1 1992

Sir:

Kindly make of record the following preliminary amendment:

IN THE TITLE:

Rewrite the title as follows:

IN THE SPECIFICATION:

Cancel pages 1-2 and substitute the following therefor -- SUMMARY OF THE INVENTION --

Page 3, lines 1-5, delete in their entirety
line 6, cancel "derivatives having" and substitute
therefor: -- In a first aspect of the invention there is provided
1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, including
certain stable forms as well as pharmaceutically acceptable salts,
which have --

B